Ana Herrero Mier (IP)

  • IBBTEC. C/ Albert Einstein 22, PCTCAN, 39011 Santander (SPAIN)
  • ana.herrero@unican.es
  • 942 206 799 ext. 25907
  • Molecular mechanisms underlying ncRNA signaling regulation during carcinogenesis
  • Emergent Principal Investigator
  • Cancer
  • Department of Cell & Molecular Signalling
Ana Herrero got her BSc in Biochemistry from the Universidad Autónoma de Madrid (2006) and joined Piero Crespo´s group (CSIC/Universidad de Cantabria) for undertaking a predoctoral position with a FPU (Formación de Profersorado Universitario) fellowship. In 2013, after finishing her doctoral thesis in the study of RAS/ERK signals in carcinogenesis, she joined Prof. Walter Kolch´s group in Systems Biology Ireland (Dublin) for starting her postdoctoral formation. There, Ana studied RAS signalling from different subcellular localization by applying a broad range of biomolecular and biological techniques. In 2016, she obtained a position at Prof. Margaret Frame´s group in Edinburgh Cancer Research Centre (Scotland, UK) for continuing her postdoctoral formation. During that scientific stage, Ana worked on the study of adhesion proteins´ nuclear role, and characterised new ILK functions in distant regions from its canonical site. In 2018, she was awarded a Juan de la Cierva-Incorporación fellowship that allowed her to generate the preliminary data for developing her own research line. Now, her project is about to study RAS-ERK regulatory mechanisms by ncRNAs.
Ana is co-author in some scientific article published in prestigious journals such as Cancer Cell, Cell Reports, Nature Communication, etc., both as first author or as collaborative authorship. She has participated in different international and national congresses and conferences, and she has contributed to the formation of young scientists and co-direction of doctoral thesis.

​​​​​​

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

Morante M, Pandiella A, Crespo P, Herrero A.

Biomolecules 2022, 12(11), 1562​.​

View more

Characterisation of a nucleo-adhesome

Characterisation of a nucleo-adhesome

Byron A, Griffith BGC, Herrero A et al.

​Nat Commun. 2022 Jun 1;13(1):3053.

View more